Iridium complex, a promising organic light-emitting diode for next generation televisiom display, emits phosphorescence. Phosphorescence is quenched by oxygen. We used this oxygen-quenching feature for imaging tumor hypoxia. Red light-emitting iridium complex Ir(btp) 2 (acac) (BTP) presented hypoxia-dependent light emission in culture cell lines, whose intensity was in parallel with HIF-1α expression. BTP was further applied to imaging five tumors (four from human origin and one from mouse origin) transplanted in athymic mice. All tumors presented a bright BTP-emitting image even 5 min after the injection. The BTP-dependent tumor image peaked at 1 to 2 h after the injection, and was then cleared off from tumors within 24 h. The minimal BTP image recognition size was 3 to 4 mm in diameter. Compared with 18 F-FDG/PET images, BTP delineated a clearer image for a tumor profile. We suggest that iridium complex has a vast potential for imaging hypoxic lesions such as tumor tissues. (150 words)
An organic light-emitting diode (OLED) is a promising device for thinner, lighter, and higher-resolution displays for next generation televisions, computers, electronic books, and billboards (1, 2) . As a low voltage-powered OLED emitter, Tang and VanSlyke introduced tris(8-hydroxyquinolinato)aluminum (Alq 3 ) to an organic thin film device (3) . In 1990
Friend and colleagues incorporated another device, a conducting polymer poly(p-phenylenevinylene), as an OLED emitter. Since then, enormous progress has been made towards the advancement of OLED emitter technology (1, 2) . These Alq 3 and their derivative devices and conducting polymers emit fluorescence, whose electroluminescence efficiency (quantum yield) is limited to 25% at maximum. In contrast to fluorescent OLED devices, a new type of organometallic phosphorescent OLEDs was introduced around the turn to the new century (4) . Such a highly attractive OLED is exemplified by iridium complex, Ir(btp) 2 (acac) (BTP; bis(2-(2'-benzothienyl)-pyridinato-N,C 3' )iridium(acetylacetonate) (5) .
Phosphorescence is superior to fluorescence in terms of its internal quantum yield.
Fluorescence emits light from singlet states whose spin statistics are predicted at a maximum 25% of charge recombinations while spin statistics of phosphorescence start from triplet states, thus the upper limit of the internal quantum yield increases from 25% to nearly 100% (2) . Furthermore, phosphorescence exhibits another conspicuous feature, oxygen quenching, by which iridium complex devices have to be shielded from the exposure to oxygen. This property suggests that the iridium complex devices emit phosphorescence, depending inversely on oxygen concentrations.
Hypoxia is highly notable in tumor tissues (6, 7) , where hypoxia-inducible factor (HIF)-1α is induced by inhibiting its degradation through the decrease in oxygen-sensing prolyl 4-hydroxylase activity (8, 9) . HIF-1α regulates a variety of gene expressions including vascular endothelial growth factor (VEGF), erythropoietin, and glucose transporter (Glut)-1.
Through HIF-1α-mediated gene expression, tumors are vascularized by VEGF to receive oxygen and nutrients for their growth in a hypoxic milieu (7) . Several hypoxia-associated probes have been developed for tumor imaging including nitroimidazole (10, 11) , Cu-diacetyl-bis(N 4 -methylthiosemicarbazone (Cu-ATSM) (12) , and fluorodeoxyglucose (FDG) (13) . Nitroimidazole and Cu-ATSM are thought to bind to macromolecules in a hypoxia-induced redox state-dependent manner. FDG is extensively taken up into tumor cells through glucose transporter 1 (Glut1), which is up-regulated by HIF-1α (7, 13) . They are used with radioisotope labeling for visualization by positron emission tomography (PET).
An optical method was demonstrated to directly detect oxygen in cells and tissues by using oxygen-dependent quenching of phosphorescence to visualize oxygen distribution in vivo (14) . For this purpose, several kinds of phosphorescent probes such as metalloporphyrins and ruthenium(II) complexes have been developed (15, 16) . Since the phosphorescence of these organic compounds was extremely weak owing to their spin-forbidden nature even under a deaerated condition, heavy metal was placed in the center to induce the active mixing effect of the spin state on the π-electronic system of the ligands for enhancement of phosphorescence intensity. Phosphorescent oxygen probes have been developed by decorating "molecular coats" to oxygen-sensitive heavy metal complexes (15,17.18) . The molecular coats protect the phosphor from the environment and give them hydrophilic nature, but their molecular size enlarges to over 2000 Da exemplified by the paradium-porphyrin complex (15) . These phosphorescent probes have been applied to measure oxygen pressure in microcapillary vessels because these probes cannot penetrate into the plasma membrane due to their size and hydrophilic nature (15, 17, 19) .
Compared with the first stage phosphorescence probes, iridium complexes possess highly phosphorescent and photostable properties which are required for use of OLED emitters. Furthermore, we are able to employ various kinds of ligands to improve the photophysical and chemical properties (absorption and emission wavelengths, solubility, toxicity, etc.) for achieving optimal properties suitable to image hypoxic tissues. In this study, we employed the well-known red-emitting iridium complex Ir(btp) 2 (acac) (BTP) (Fig. 1a) as a phosphorescent probe. The red phosphorescence of BTP is advantageous for tissue penetrance, and its moderately long lifetime (5.8 μs in deaerated 1,2-dichloroethane) is favorable for oxygen-induced quenching. Based on these reasons, we applied this phosphorescent probe for hypoxic tumor imaging to test its feasibility.
RESULTS

Photophysical properties of BTP complexes
Since the chemical structure of BTP appears lipophilic ( Fig. 1a) , we examined its uptake into an artificial membrane composed of dimyristoyl-L-α-phosphatidylcholine (DMPC, 1 mM).
Indeed, over 98% of BTP was partitioned into the membrane when BTP (10 μM) was dissolved in Tris-HCl buffer at 35°C. We then investigated the photophysical properties of BTP in DMPC liposome as well as in 1,2-dichloroethane and n-hexane solutions. BTP in a deaerated 1,2-dichloroethane solution showed the first absorption maximum at 483 nm with a molar absorption coefficient of 6,100 M -1 cm -1 , and showed intense phosphorescence from a ligand-centered ππ*state (promotion of a π-electron to an antibonding π* orbital) with significant admixtures of metal-to-ligand charge transfer (electron promotions from metal-centered to ligand-centered orbitals) character at 616 nm (Fig. 1b) . where Φ p and τ p , respectively, are the phosphorescence quantum yield and phosphorescence lifetime at an oxygen partial pressure pO 2 , and k q is a bimolecular quenching rate constant (20) .
At 35°C, the k q value in n-hexane was determined to be 5. will be quenched in the tissue pO 2 milieu of 60 mmHg. Since pO 2 = 60 mmHg is not hypoxic as a tissue pO 2 (7) , BTP is presumed to become phosphorescent at lower pO 2 than 60 mmHg, so it appears to be applicable to hypoxic tissue pO 2 estimation.
Iridium complex BTP to culture cells in a hypoxic milieu
Since the oxygen quenching feature of BTP appeared to be regulated in a physiological tissue pO 2 milieu by the photophysical evaluation, we examined the oxygen quenching using culture cell lines. Three cell lines, human uterine cancer-derived HeLa, Chinese hamster ovary-derived CHO, and human glioma-derived U251, were placed in a 5% O 2 culture condition. In normoxia, the three cell lines did not exhibit notable phosphorescence when loaded with BTP (50 μM) ( Fig. 2a) . In contrast, the three cell lines emitted bright red phosphorescence in a 5% O 2 culture ( Fig. 2a) . We then observed the phosphorescence of BTP in decreasing O 2 levels from 20% to 2.5% using HeLa cells ( Fig. 2b, upper panel) . With a decrease in O 2 concentration, the phosphorescence increased in an inverted manner. Likewise, HIF-1α was increasingly immunostained with a decrease in O 2 levels ( Fig. 2b , lower panel).
In accordance with this, HIF-1α protein gradually displayed an intensive band with the increasing intensity of phosphorescence ( Fig. 2c) . Since we observed the BTP phosphorescence emission in a hypoxia-dependent manner, we tested this probe to image tumors transplanted in athymic nude mice.
BTP to tumor-bearing nude mice
We used five culture cell lines for transplantation; human oral squamous carcinoma-derived SCC-7, human glioma-derived U87, human lymphoma-derived RAMOS, human colon carcinoma-derived HT-29, and mouse lung cancer-derived LL-2. Tumor size varied from 10 to 15 mm. The histopathological features of each tumor were examined as follows: SCC-7, poorly differentiated carcinoma without any keratinization; U87, spindle-shaped glial cells with marked atypia; RAMOS, medullary growth of large atypical lymphocytes; HT-29, poorly differentiated adenocarcinoma cells forming tubular structures; and LL-2, poorly differentiated adenocarcinoma cells with intracytoplasmic vacuoles (Supplementary Fig. 1 ). Tumors grown from culture cells tended to show undifferentiated features. We then measured pO 2 by an oxygen monitoring probe, and found that median pO 2 ranged from 18 to 21 mmHg (Table 1) .
Thus, the pO 2 of each tumor was lower than that of end-capillary blood whose pO 2 ranges from 45 to 50 mmHg (7) . However, since Höckel and Vaupel stated that the critical pO 2 below 8-10 mmHg is associated with detrimental hypoxic changes such as decrease in cellular ATP levels (8) , the pO 2 levels in the five tumors appear to come under the moderate hypoxia criteria. To examine the expression of HIF-1α, we immunostained HIF-1α in the five tumors.
HIF-1α was well stained in SCC-7 and HT-29 tumors, but was not well notable in the other tumors ( Supplementary Fig. 1 ).
We dissolved BTP in dimethylsulfoxide (DMSO) because it was lipophilic. The BTP dose was determined using SCC-7 tumor-bearing mice by injecting 25 nmol, 125 nmol, 250 nmol, and 500 nmol/mouse, and 250 and 500 nmol BTP/mouse was found to clearly depict a tumor image ( Supplementary Fig. 2 ). BTP (250 nmol/100 μl DMSO) was injected from the tail vein under pentobarbital anesthesia. Each tumor-bearing mouse was placed in a dark box of the Maestro In-Vivo imaging System. Luminescence was detected 5 min after the injection in all five tumors, and it increased gradually to a 1 h-point (Fig. 3a) . The shape and position of the luminescence spectra emitted from the tumors were identical with those of the phosphorescence spectrum of BTP shown in Fig. 1b , suggesting that BTP chemical structure was maintained in a spectrum basis (data not shown). Extra-tumor regions are generally non-luminescent, but when anesthesia is overdosed, the forearm, peri-oral and peri-nasal regions began to turn red.
We then determined the fate of BTP using SCC-7 tumors in athymic nude mice. The intensity of BTP was highest at 2 h after the injection, then declined gradually towards the 24-h point, when the tumor was not imaged (Fig. 3b) . We measured the pO 2 level before and periodically after the BTP administration, and found that pO 2 levels are not affected by BTP administration even after the peak of BTP phosphorescence (data not shown).
Detection limit of tumor size and imaging depth
We examined the detection limit of BTP-imaged tumor size. SCC-7 cells were injected into athymic nude mice and their tumor size was monitored daily. When the tumor reached 2 mm and more in diameter, we began to assess BTP imaging. When a tumor grew to 4 mm in diameter, its BTP-imaging was reliably detected (Fig. 4) .
One of the drawbacks of luminescent imaging is the penetration limit of luminescence.
Although a red to near-infrared wavelength (>630 nm) is preferable for tissue penetration both in excitation and emission, the excitation wavelength of BTP is 483 nm at maximum although its emission is 616 nm at its first peak and 680 nm at its second peak (Fig. 1b) . We measured the detection limit of BTP-imaging by placing a 1.2 mm slice of beef meat on a BTP gel composed of polyacrylamide. We could detect the BTP-imaging at a depth of 4.8 mm by 20 nmol BTP and 7.2 mm by 200 nmol BTP, but it was more difficult to detect a depth of 8.4 mm from the surface (Supplementary Fig. 3) . Thus, to obtain much deeper tissue penetration, BTP should be modified for excitation by a red to near-infrared wavelength.
Comparison of BTP-imaging with 18 F-FDG-imaging
The BTP image depicted tumor profiles almost accurately in each tumor. Since FDG-PET is routinely used for screening dormant tumors in medicine, we compared the BTP-imaging with FDG-PET imaging. We selected similar size tumors grown on the right pelvic region, one for BTP-imaging and the other for 18 F-FDG-imaging. The BTP image was limited to tumor profiles in each tumor, whereas the 18 F-FDG-image looked vague in all five mice. We could barely find a limited image in the U87MG, and HT-29 tumors (Supplementary Fig. 4) . Apart from tumor-imaging, the 18 F-FDG-image was distributed to non-tumor tissues such as the brain and the heart, and resulted in widely spreading images in each mouse. Thus, we suggest that BTP-image is much clearer than 18 F-FDG-image.
Toxicity
As the first step for evaluating BTP toxicity, we examined cell viability using HeLa cells by trypan blue dye-exclusion assay and apoptosis by staining with Hoechst 33342 DNA binding dyes plus propidium iodide fluorescence. We used cholesterol as a negative control and 7-ketocholesterol as a positive control because both are lipophilic similar to BTP (21). Both cell viability and apoptosis by BTP were similar to those in the cholesterol control ( Supplementary Fig. 5 ).
DISCUSSION
We demonstrated a promising potential of phosphorescent OLED, iridium complex, for tumor imaging. To visualize hypoxic tissues, phosphorescence is superior to fluorescence because of one of its specific features, oxygen quenching. Using this feature, phosphorescent probes such as BTP can be visualized in a hypoxic milieu such as tumors. Tumors were visible even 5 min after the BTP injection (Figs. 3a) . The luminescent region became widespread over the tumor profile 1 to 2 h after the BTP injection, and disappeared within 24 h (Fig. 3b) . In a tumor-bearing mouse, BTP is distributed systemically to its whole body, and emits phosphorescence where oxygen supply is insufficient. In this sense, iridium complex is distinct in its luminescence emission in comparison to other tumor-detecting probes, such as nitroimidazole, Cu(II)-ATSM, and 18 F-FDG. In other words, iridium complex is a hypoxia-sensing emitter, while the above three are a hypoxia-accumulating emitter. For example, nitroimidazole accumulates in a hypoxic tissue where the nitro residues are reduced by the lack of sufficient oxygen, and a reduced form of nitroimidazole is thought to bind to macromolecules (11, 22) . Nitroimidazole has been developed for use with a radioisotope-labeled PET probe, such as [ 18 F]-fluoromisonidazole (FMISO) (23) and
[ 18 F]-fluoroetanidazole (24) . Cu(II)-ATSM is also reduced in hypoxic tissue to release Cu(I),
which is thought to bind to macromolecules. Thus, when Cu is radiolabeled as 60 Cu, 61 Cu, 62 Cu, or 64 Cu, radiolabeled Cu is trapped in the hypoxic tissue (25) . These probes should be radiolabeled for PET and requires cost-taking PET facilities and equipments.
Recently, quantum dots (QDs) have attracted much attention as a fluorescent probe for tumor imaging, although tumor imaging mechanisms of QDs do not depend on hypoxia (26, 27) . But tumor vasculature has large penetration gaps for macromolecules such as nanometer-size QD particles. Furthermore, QD has been extensively modified by decorating a variety of molecules for better trapping to tumor tissues (28, 29) . QDs are made of CdSe-ZnS in their core shell (27) . Thus, QDs are used for shielding with a safe lining because Cd is toxic (30) . Although QDs may be safe in the body, excreted QDs from animals, and animals retained with QDs have to be disposed safely. Thus, the toxicity problem of QDs has not been settled yet (30, 31) . On the other hand, iridium complex appears to be safe based on a preliminary toxicity experiment (Supplementary Fig. 5 ). We also noted that mice were healthy for over three months after a high dose injection of BTP (data not shown). 18 F-FDG is most frequently used for PET as a probe for tumor imaging (32) . FDG is taken up to cells through Glut1, and its retention to tumors depends on the balance between hexokinase and glucose-6-phosphatase (G6Pase) activities (13) . In a hypoxic condition, Glut1
is induced by HIF-1α for increasing uptake of glucose (8) (9) (10) . FDG is phosphorylated to FDG-6-P by hexokinase, but FDG-6-P cannot be converted further to fluorodeoxyfructose 6-phosphate by phosphohexose isomerase because hydroxyl residue at position 2 is replaced by fluorine. Conversely, FDG-6-P can be reversed to FDG by G6Pase if G6Pase activity is high, and as a result, FDG may be removed out from the cell. Since tumors such as early prostate cancer and well-differentiated hepatoma have high G6Pase activity, FDG/PET is not adequate for the detection of these tumors (13) . In this study, FDG/PET did not depict a clear tumor image in all five tumors compared with BTP-imaged tumors (Supplementary Fig. 4) .
FDG/PET resulted in bright images in non-tumor-residing regions, perhaps reflecting an
FDG-incorporating brain, heart, and muscle images in all mice. Further, FDG/PET imaging barely delineates a tumor profile. Thus, the BTP image looks much better in depicting a tumor profile than FDG image.
But luminescent probes have an inevitable drawback, that is, their weak tissue penetration capacity, which is reportedly about 1 cm deep even when near-infrared wavelength light was used (26) . The phosphorescence of BTP appears in the red to near-infrared region (>615nm), while the excitation wavelength is limited to the visible light region (445-490nm). Indeed, when we placed a mouse with the tumor underneath, we could not detect the BTP-imaged tumor profile perhaps due to its approximately 3 cm-thick body.
To determine a depth-dependent detection limit, we placed a 1. Fig. 3) . We further improved BTP by adding phenyl residues (BTQ) thus making the excitation wavelength shift 540 nm longer. But the penetration limit stayed in a similar range to that of BTP (data not shown). Thus, BTP imaging is preferable when tumors are situated close to the tissue surface. In this sense, we suggest that BTP imaging may be a promising technique for the detection of gastrointestinal tumors involving mucosal to submucosal layers with use of an endoscope. Since the detection limit of tumor size was estimated to be approximately 4 mm in diameter (Fig. 4) , microadenoma and microcancer appear to be a target of BTP imaging. We suggest that iridium complex has practical feasibility for tumor hypoxia imaging, and it will have a promising potential for a hypoxia-indicating chemical probe in assistance with other imaging techniques such as PET scanning and endocytoscopy. Ltd., Tokyo, Japan). The pO 2 monitoring system has been commonly used in physiologic and anesthetic research, and details of this machine have been reported previously (33) . An oxygen electrode probe of a 200 μm diameter was inserted into tumors of immobilized mice without general anesthesia, and then pO 2 was measured at least 10 different points in each tumor and the mean pO 2 was calculated. After the measurement, the tumors were excised and weighed. 
METHODS
